Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.
In recent years, numerous substances have been identified as so-called "endocrine disruptors" because exposure to them results in disruption of normal endocrine function with possible adverse health outcomes. The pathologic and behavioral abnormalities attributed to exposure to endocrine disruptors like bisphenol-A (BPA) have been studied in animals. Mental conditions ranging from cognitive impairment to autism have been linked to BPA exposure by more than one investigation. Concurrent with these developments in BPA research, schizophrenia research has continued to find evidence of possible endocrine or neuroendocrine involvement in the disease. Sufficient information now exists for a comparison of the neurotoxicological and behavioral pathology associated with exposure to BPA and other endocrine disruptors to the abnormalities observed in schizophrenia. This review summarizes these findings and proposes a theory of endocrine disruption, like that observed from BPA exposure, as a pathway of schizophrenia pathogenesis. The review shows similarities exist between the effects of exposure to BPA and other related chemicals with schizophrenia. These similarities can be observed in 11 broad categories of abnormality: physical development, brain anatomy, cellular anatomy, hormone function, neurotransmitters and receptors, proteins and factors, processes and substances, immunology, sexual development, social behaviors or physiological responses, and other behaviors. Some of these similarities are sexually dimorphic and support theories that sexual dimorphisms may be important to schizophrenia pathogenesis. Research recommendations for further elaboration of the theory are proposed.
Brown
James S
JS
Department of Psychiatry, VCU School of Medicine, Richmond, VA, USA. jbrown2185@aol.com
D001253:Astrocytes / Q000187:drug effects / Q000473:pathology; D001559:Benzhydryl Compounds; D001921:Brain / Q000033:anatomy & histology* / Q000503:physiopathology*; D004967:Estrogens / Q000502:physiology; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology*; D009836:Oligodendroglia / Q000187:drug effects / Q000473:pathology; D010121:Oxytocin / Q000502:physiology; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology*; D011374:Progesterone / Q000502:physiology; D011582:Psychological Theory; D012559:Schizophrenia / Q000473:pathology / Q000503:physiopathology*; D000098826:Bisphenol A Compounds
D001559:Benzhydryl Compounds; D004967:Estrogens; D016166:Free Radical Scavengers; D010121:Oxytocin; D010636:Phenols; D011374:Progesterone; C006780:bisphenol A; D000098826:Bisphenol A Compounds